Short-course antiretroviral therapy in primary HIV infection.

BACKGROUND Short-course antiretroviral therapy (ART) in primary human immunodeficiency virus (HIV) infection may delay disease progression but has not been adequately evaluated. METHODS We randomly assigned adults with primary HIV infection to ART for 48 weeks, ART for 12 weeks, or no ART (standard of care), with treatment initiated within 6 months after seroconversion. The primary end point was a CD4+ count of less than 350 cells per cubic millimeter or long-term ART initiation. RESULTS A total of 366 participants (60% men) underwent randomization to 48-week ART (123 participants), 12-week ART (120), or standard care (123), with an average follow-up of 4.2 years. The primary end point was reached in 50% of the 48-week ART group, as compared with 61% in each of the 12-week ART and standard-care groups. The average hazard ratio was 0.63 (95% confidence interval [CI], 0.45 to 0.90; P=0.01) for 48-week ART as compared with standard care and was 0.93 (95% CI, 0.67 to 1.29; P=0.67) for 12-week ART as compared with standard care. The proportion of participants who had a CD4+ count of less than 350 cells per cubic millimeter was 28% in the 48-week ART group, 40% in the 12-week group, and 40% in the standard-care group. Corresponding values for long-term ART initiation were 22%, 21%, and 22%. The median time to the primary end point was 65 weeks (95% CI, 17 to 114) longer with 48-week ART than with standard care. Post hoc analysis identified a trend toward a greater interval between ART initiation and the primary end point the closer that ART was initiated to estimated seroconversion (P=0.09), and 48-week ART conferred a reduction in the HIV RNA level of 0.44 log(10) copies per milliliter (95% CI, 0.25 to 0.64) 36 weeks after the completion of short-course therapy. There were no significant between-group differences in the incidence of the acquired immunodeficiency syndrome, death, or serious adverse events. CONCLUSIONS A 48-week course of ART in patients with primary HIV infection delayed disease progression, although not significantly longer than the duration of the treatment. There was no evidence of adverse effects of ART interruption on the clinical outcome. (Funded by the Wellcome Trust; SPARTAC Controlled-Trials.com number, ISRCTN76742797, and EudraCT number, 2004-000446-20.).

[1]  C. B. Hare,et al.  The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. , 2012, The Journal of infectious diseases.

[2]  B. Berkhout,et al.  In HIV-1 pathogenesis the die is cast during primary infection , 2007, AIDS.

[3]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[4]  M. Prins,et al.  Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. , 2010, AIDS research and human retroviruses.

[5]  Sigall K. Bell,et al.  Clinical management of acute HIV infection: best practice remains unknown. , 2010, The Journal of infectious diseases.

[6]  B. Gazzard,et al.  Initiation of Antiretroviral Therapy During Recent HIV-1 Infection Results in Lower Residual Viral Reservoirs , 2004, Journal of acquired immune deficiency syndromes.

[7]  Anthony D. Kelleher,et al.  Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4+ T Cells , 2009, Journal of Virology.

[8]  Lei Wang,et al.  A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. , 2006, The Journal of infectious diseases.

[9]  Peter Reiss,et al.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.

[10]  C. Speil.  Incomplete Peripheral CD4+ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment , 2009 .

[11]  C. Tremblay,et al.  Effect of antiretroviral therapy on HIV-1 genetic evolution during acute infection , 2011, International journal of STD & AIDS.

[12]  Jeffrey N. Martin,et al.  Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Michael P Busch,et al.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection , 2003, AIDS.

[14]  H. Schuitemaker,et al.  No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial , 2012, PLoS medicine.

[15]  J. Parry,et al.  Assays for the detection of recent infections with human immunodeficiency virus type 1. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[16]  P. Easterbrook,et al.  Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  James M Robins,et al.  The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals , 2010, AIDS.

[18]  E. Rosenberg,et al.  Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4+ T Cells , 2009, Journal of Virology.

[19]  M. Altfeld,et al.  Acute HIV-1 infection: what's new? Where are we going? , 2010, The Journal of infectious diseases.

[20]  A. Walker,et al.  Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy , 2007, AIDS.

[21]  S. Khoo,et al.  Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  J. Ananworanich,et al.  Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs , 2005, AIDS.

[23]  A. Phillips,et al.  Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. , 2008, Annals of internal medicine.

[24]  M. McElrath,et al.  Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. , 2000, The Journal of infectious diseases.

[25]  K. Metzner,et al.  Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection , 2010, PloS one.

[26]  B. Haynes,et al.  Acute HIV-1 Infection. , 2011, The New England journal of medicine.

[27]  H. Günthard,et al.  Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna , 2011, Antiviral therapy.

[28]  J. Weber,et al.  Human immunodeficiency virus (HIV)‐specific T helper responses fail to predict CD4+ T cell decline following short‐course treatment at primary HIV‐1 infection , 2008, Clinical and experimental immunology.

[29]  Tommy F. Liu,et al.  Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  B. Walker,et al.  Characterization of HIV-1-specific T-helper cells in acute and chronic infection. , 1999, Immunology letters.

[31]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[32]  Elizabeth Connick,et al.  Immunophenotypic alterations in acute and early HIV infection. , 2007, Clinical immunology.

[33]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[34]  J. Weber,et al.  Primary HIV infection: to treat or not to treat? , 2008, Current opinion in infectious diseases.

[35]  F. A. Monteiro.  O Abandono do Monumento: O Caso do Hospital Escola São Francisco de Assis , 2014 .

[36]  Kholoud Porter,et al.  Determinants of survival following HIV-1 seroconversion after the introduction of HAART , 2003, The Lancet.